
PharmaTher Holdings Ltd. — Investor Relations & Filings
PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News release - English.pdf | 2026-05-13 | English | |
| 52-109FV2 - Certification of interim filings - CFO (E).pdf | 2026-04-29 | English | |
| Interim MD&A - English.pdf | 2026-04-29 | English | |
| Interim financial statements/report – English.pdf | 2026-04-29 | English | |
| News release - English.pdf | 2026-04-21 | English | |
| News release - English.pdf | 2026-04-20 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47774451 | News release - English.pdf | 2026-05-13 | English | ||
| 47774455 | 52-109FV2 - Certification of interim filings - CFO (E).pdf | 2026-04-29 | English | ||
| 47774467 | Interim MD&A - English.pdf | 2026-04-29 | English | ||
| 47774471 | Interim financial statements/report – English.pdf | 2026-04-29 | English | ||
| 34766307 | News release - English.pdf | 2026-04-21 | English | ||
| 34693027 | News release - English.pdf | 2026-04-20 | English | ||
| 34691251 | News release - English.pdf | 2026-04-20 | English | ||
| 34647361 | News release - English.pdf | 2026-04-16 | English | ||
| 34647337 | News release - English.pdf | 2026-04-16 | English | ||
| 34431045 | News release - English.pdf | 2026-04-13 | English | ||
| 34412733 | News release - English.pdf | 2026-04-13 | English | ||
| 47774475 | News release - English.pdf | 2026-03-26 | English | ||
| 47774490 | News release - English.pdf | 2026-03-03 | English | ||
| 32392603 | News release - English.pdf | 2026-02-02 | English | ||
| 47774494 | 52-109FV2 - Certification of interim filings - CFO (E).pdf | 2026-01-30 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BriaCell Therapeutics Corp.
Developing targeted cellular immunotherapies using whole-ce…
|
BCTX | CA | Manufacturing |
|
BridgeBio Oncology Therapeutics, Inc.
Clinical-stage biopharma developing inhibitors for genetica…
|
BBOT | US | Manufacturing |
|
BridgeBio Pharma, Inc.
Develops transformative medicines for genetic diseases and …
|
BBIO | US | Manufacturing |
|
Brightgene Bio-Medical Technology Co., Ltd.
Research-driven developer of complex APIs, high-end generic…
|
688166 | CN | Manufacturing |
|
BRIGHT MINDS BIOSCIENCES INC.
Develops selective serotonin agonists for neurological and …
|
DRUG | US | Manufacturing |
|
BrightPath Biotherapeutics Co., Ltd.
A clinical-stage biopharma company developing cancer immuno…
|
4594 | JP | Manufacturing |
|
Brii Biosciences Limited
Developing first-in-class therapies targeting infectious an…
|
2137 | KY | Manufacturing |
|
BRISTOL MYERS SQUIBB CO
A global biopharmaceutical company that discovers, develops…
|
BMY | US | Manufacturing |
|
BROOKS LABORATORIES LIMITED
Pharmaceutical manufacturer specializing in CRAMS and diver…
|
BROOKS | IN | Manufacturing |
|
BUKWANG PHARMACEUTICAL IND CO.,LTD
An R&D-focused company developing drugs for CNS disorders a…
|
003000 | KR | Manufacturing |
PharmaTher Holdings Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/47881/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=47881 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=47881 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=47881 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 47881}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PharmaTher Holdings Ltd. (id: 47881)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.